Immunome Q1 net loss $41.6M; cash $317.3M; varegacestat data expected H2 2025

Immunome Inc.

2025-Q1 EPS reported -$0.52 revenue$2,926,000

Net loss of $41.6M for Q1 2025; R&D expense $36.9M, G&A $10.7M.
Cash, equivalents and marketable securities $317.3M as of March 31, 2025; expected to fund operations into 2027.
Phase 3 RINGSIDE trial of varegacestat fully enrolled; topline data expected in second half of 2025.
Phase 1 for IM-1021 (ROR1 ADC) ongoing; IM-3050 (FAP radiotherapy) IND cleared, trial to start H2 2025.
Amended 2024 Inducement Plan to increase reserved shares from 2M to 3.5M for new-hire equity grants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.